Show simple item record

Characteristics of an adenosine A1 binding site in human placental membranes

dc.contributor.authorWork, Carolynen_US
dc.contributor.authorHutchison, Kevin A.en_US
dc.contributor.authorPrasad, Madhu A.en_US
dc.contributor.authorBruns, Robert F.en_US
dc.contributor.authorFox, Irving H.en_US
dc.date.accessioned2006-04-07T20:57:17Z
dc.date.available2006-04-07T20:57:17Z
dc.date.issued1989-01en_US
dc.identifier.citationWork, Carolyn, Hutchison, Kevin, Prasad, Madhu, Bruns, Robert F., Fox, Irving H. (1989/01)."Characteristics of an adenosine A1 binding site in human placental membranes." Archives of Biochemistry and Biophysics 268(1): 191-202. <http://hdl.handle.net/2027.42/28151>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6WB5-4DPC12P-XP/2/ce55fe6f5f194fb7236a1264aa417861en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/28151
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2912375&dopt=citationen_US
dc.description.abstractBinding sites were solubilized from human placental membrane using 1.5% sodium cholate and were assayed using polyethylene glycol precipitation. These soluble binding sites had properties of an adenosine A1 binding site. 2-[3H]Chloroadenosine and N-[3H]-ethylcarboxamidoadenosine (NECA) binding were time dependent and reversible. Scatchard plots indicate two classes of binding sites with Kd values of 6 and 357 n for 2-chloro[8-3H]adenosine and 0.1 and 26 n with [3H]NECA. The specificity of [3H]NECA binding was assessed by the ability of adenosine analogs to compete for binding sites. Using this approach the estimated IC50 values were 60 n for N6-((R)-1-methyl-2-phenylethyl)adenosine (R-PIA), 160 n for S-PIA, 80 n for NECA, and 20 n for 2-chloroadenosine. Binding of [3H]NECA to the soluble sites is inhibited to 48% of the control value by 100 [mu] guanylyl-5'-imidodiphosphate (Gpp(NH)p). The IC50 value for NECA binding to the soluble binding site was increased from 80 n to 1500 by Gpp(NH)p. There was a shift of binding affinity from a mixture of high and low affinity to only low affinity with 100 [mu] Gpp(NH)p. Despite these alterations a NECA prelabeled molecular species of 150 kDa did not decrease in molecular weight upon the addition of 100 [mu] Gpp(NH)p during high-performance liquid chromatography on a Superose 12 column. Other evidence to support the concept of preferential solubilization and assay of a small population of A1 binding sites was obtained. Following solubilization adenosine A2-like binding sites could be detected only in reconstituted vesicles. The existence of small amounts of A1 binding sites in intact human placental membranes was directly demonstrated using the A1 agonist ligand N6-[3H]cyclohexyladenosine and the A1 antagonist ligand 8-[3H]cyclopentyl-1,3-dipropylxanthine. JAR choriocarcinoma cells have "A2-like" membrane binding sites. In contrast to placental membranes, only A2-like binding sites could be solubilized from JAR choriocarcinoma cells. These observations indicate that human placental membranes contain adenosine A1 binding sites in addition to A2-like binding sites. These sites are guanine nucleotide sensitive, but do not shift to a lower molecular weight form upon assumption of a low affinity state.en_US
dc.format.extent1140056 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleCharacteristics of an adenosine A1 binding site in human placental membranesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumHuman Purine Research Center, Departments of Internal Medicine and Biological Chemistry, University Hospital, The University of Michigan, Ann Arbor, Michigan 48109-0108, U.S.A.en_US
dc.contributor.affiliationumHuman Purine Research Center, Departments of Internal Medicine and Biological Chemistry, University Hospital, The University of Michigan, Ann Arbor, Michigan 48109-0108, U.S.A.en_US
dc.contributor.affiliationumHuman Purine Research Center, Departments of Internal Medicine and Biological Chemistry, University Hospital, The University of Michigan, Ann Arbor, Michigan 48109-0108, U.S.A.en_US
dc.contributor.affiliationumHuman Purine Research Center, Departments of Internal Medicine and Biological Chemistry, University Hospital, The University of Michigan, Ann Arbor, Michigan 48109-0108, U.S.A.en_US
dc.contributor.affiliationotherDepartment of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105, U.S.A.en_US
dc.identifier.pmid2912375en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/28151/1/0000603.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0003-9861(89)90579-1en_US
dc.identifier.sourceArchives of Biochemistry and Biophysicsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.